Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
Moustafa Abdou, Author and Founder of AskHematologist.com, shared a post on LinkedIn:
”Cold Agglutinin Disease (CAD)
Cold Agglutinin Disease is a rare but clinically significant complement-mediated autoimmune hemolytic anemia driven by cold-reactive IgM antibodies.
What makes CAD particularly important is its dual presentation: chronic hemolysis alongside cold-induced circulatory symptoms such as acrocyanosis and Raynaud-like changes.
Diagnosis requires a high index of suspicion, with a characteristic C3d-positive direct antiglobulin test and evidence of complement activation.
Management has evolved significantly in recent years.
While cold avoidance and rituximab-based therapy remain important, targeted complement inhibition (e.g. sutimlimab) is transforming outcomes in selected patients.
Early recognition is key to preventing complications and improving quality of life.”
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids